{"product_id":"ynbaiyao-business-model-canvas","title":"Yunnan Baiyao Group Business Model Canvas","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eUnlock a healthcare group's strategic DNA with a compact Business Model Canvas for investors\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eUnlock Yunnan Baiyao Group’s strategic DNA with our concise Business Model Canvas—three to five key sentences revealing how the firm creates value, leverages R\u0026amp;D and distribution, and monetizes brand trust. Ideal for investors, consultants, and founders seeking actionable takeaways. Download the full Word\/Excel canvas to benchmark, adapt, and accelerate your strategy now.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eP\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eartnerships\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHerbal suppliers and raw-material growers\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eLong-term contracts with herbal suppliers and GAP-certified plantations secure consistent, quality-assured sourcing of key medicinal herbs and enable traceability programs to manage variability. Joint agronomy initiatives with growers stabilize yields and mitigate climate and supply risks while enabling cost-control measures. These partnerships underpin product potency and quality differentiation for Yunnan Baiyao Group.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHospitals, clinics, and healthcare professionals\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eClinical partners drive adoption via evidence-based use and formulary inclusion, with hospitals and NMPA-regulated procurement channels ensuring institutional uptake. Surgeon, ER, and TCM practitioner endorsement strengthens credibility and repeat utilization across acute and traditional care pathways. Co-developed protocols and training with hospital teams improve outcomes and safety, while structured feedback loops feed post-market surveillance and product refinement under NMPA reporting requirements.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eUniversities, research institutes, and CROs\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eCollaborations with universities, research institutes, and CROs accelerate pharmacology, formulation optimization, and trials, cutting typical R\u0026amp;D timelines; leveraging over 200 Chinese CROs provides scalable clinical and regulatory execution capacity. Access to advanced labs and talent reduces development risk, while joint IP and peer‑review publications bolster scientific legitimacy for TCM‑modern integration in 2024.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRetail pharmacies, e-commerce platforms, and distributors\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eChannel partners extend Yunnan Baiyao reach across urban tiers and rural clinics via China’s \u0026gt;400,000 retail pharmacies, with e-commerce tapping a national online pharma market ~RMB 400 billion in 2023; pharmacists drive point-of-sale recommendations, e-commerce supplies nationwide coverage plus sales and consumer-data insights, and distributors optimize inventory, cold-chain integrity and last-mile economics.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003ePharmacies: pharmacist-led POS recommendations\u003c\/li\u003e\n\u003cli\u003eE-commerce: national reach, data-driven promotions (online market ~RMB 400B in 2023)\u003c\/li\u003e\n\u003cli\u003eDistributors: inventory, cold-chain, last-mile efficiency\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eContract manufacturers and regulatory\/industry bodies\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eContract manufacturers (CMOs) provide surge capacity and cost flexibility while adhering to GMP, enabling Yunnan Baiyao to scale production without large capital outlays; group revenue stood around RMB 36 billion in 2023, highlighting outsourcing leverage. Close engagement with NMPA and standards bodies accelerates approvals and market access. Joint quality audits and serialization programs strengthen supply integrity, and industry alliances back policy advocacy and best-practice sharing.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eCMO surge capacity: supports peak output without capex\u003c\/li\u003e\n\u003cli\u003eNMPA engagement: faster regulatory pathways\u003c\/li\u003e\n\u003cli\u003eJoint audits\/serialization: reduces supply risk\u003c\/li\u003e\n\u003cli\u003eIndustry alliances: policy \u0026amp; best-practice coordination\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGAP farms, CMOs and \u003cstrong\u003e200\u003c\/strong\u003e+ CROs fuel \u003cstrong\u003eRMB 36B\u003c\/strong\u003e; \u0026gt; \u003cstrong\u003e400k\u003c\/strong\u003e pharmacies\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eLong-term herb contracts, GAP farms and CMOs secure quality and surge capacity; group revenue ~RMB 36 billion in 2023. Clinical and hospital partners drive institutional adoption and post-market surveillance; collaborations with \u0026gt;200 CROs speed trials. Channel partners reach China’s \u0026gt;400,000 pharmacies and tap an online pharma market ~RMB 400 billion in 2023.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003ePartner\u003c\/th\u003e\n\u003cth\u003eRole\u003c\/th\u003e\n\u003cth\u003eKey 2023 Metric\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eHerb suppliers\u003c\/td\u003e\n\u003ctd\u003eQuality\/traceability\u003c\/td\u003e\n\u003ctd\u003eGAP farms\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCROs\u003c\/td\u003e\n\u003ctd\u003eR\u0026amp;D\/Trials\u003c\/td\u003e\n\u003ctd\u003e\u0026gt;200\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eChannels\u003c\/td\u003e\n\u003ctd\u003eDistribution\u003c\/td\u003e\n\u003ctd\u003e\u0026gt;400,000 pharmacies; online ~RMB 400B\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCMOs\u003c\/td\u003e\n\u003ctd\u003eSurge capacity\u003c\/td\u003e\n\u003ctd\u003eSupports scaling\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eA comprehensive Business Model Canvas for Yunnan Baiyao Group detailing customer segments, channels, value propositions, revenue streams, key activities, partners, resources, cost structure and governance, reflecting real-world operations, competitive advantages and linked SWOT insights—designed for investors, analysts and managers to support strategic decisions and funding discussions.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eCondenses Yunnan Baiyao Group’s complex pharma and consumer-healthcare strategy into a one-page Business Model Canvas, relieving analysis bottlenecks and enabling fast, shareable team alignment.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eA\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003ectivities\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eR\u0026amp;D in TCM and modern pharmaceuticals\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eConduct phytochemical research, mechanism studies and formulation innovation, supported by R\u0026amp;D investment of RMB 1.02 billion in 2023 and ongoing into 2024. Run preclinical and clinical trials to validate efficacy and safety under NMPA standards and expand indications. Manage IP filing for formulations, processes and delivery systems to protect innovations. Continuously improve flagship and pipeline products based on trial and real-world evidence.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGMP manufacturing and scale-up\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eAs of 2024 Yunnan Baiyao operates standardized GMP plants for five dosage forms — powders, aerosols, plasters, capsules and toothpaste — using process controls, automation and lean practices to raise yields and reduce variability. New formulations are scaled from pilot to commercial batches through validated tech-transfer protocols and staged scale-up. Equipment validation and monthly continuous-improvement cycles sustain compliance and throughput.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eQuality assurance and pharmacovigilance\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eYunnan Baiyao Group (SZSE: 000538) enforces stringent raw-material testing and in-process controls across its manufacturing lines to safeguard product integrity. The company tracks adverse events and real-world performance across hospital, retail and e-commerce channels via centralized pharmacovigilance systems. Regular supplier audits and GS1-compatible lot traceability reduce supply-chain risk. Quality systems are aligned with NMPA requirements and WHO GMP standards.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eBranding, medical affairs, and consumer education\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cpbranding medical affairs and consumer education develop evidence-backed narratives for clinicians consumers deliver detailing cme patient leverage digital marketing kols community outreach run proactive reputation crisis communications align with china internet user base of about billion to scale reach.\u003e\n\u003cul class=\"lst_crct\"\u003e\u003c\/ul\u003e\n\u003cli\u003eEvidence-based CME and detailing\u003c\/li\u003e\n\u003cli\u003eDigital marketing + KOLs targeting 1.05B internet users\u003c\/li\u003e\n\u003cli\u003ePatient education and community outreach\u003c\/li\u003e\n\u003cli\u003eProactive reputation and crisis management\u003c\/li\u003e\n\u003c\/pbranding\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDistribution and channel management\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eYunnan Baiyao forecasts demand, manages inventories and optimizes logistics across tiers, leveraging regional promotions and category management to support shelf presence and traffic; in 2024 China’s retail pharmaceutical market exceeded RMB 1.2 trillion with online channels ~30%, intensifying omni-channel replenishment needs.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eForecasting: demand-driven SKU planning\u003c\/li\u003e\n\u003cli\u003eInventory: region-tier replenishment\u003c\/li\u003e\n\u003cli\u003eChannel: negotiate shelf\/traffic with distributors, pharmacies, platforms\u003c\/li\u003e\n\u003cli\u003eData: assortment, pricing, promo ROI\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eR\u0026amp;D \u003cstrong\u003eRMB 1.02B\u003c\/strong\u003e, 5 GMP forms; China pharma market \u0026gt;RMB 1.2T\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eR\u0026amp;D: RMB 1.02 billion invested in 2023, continued into 2024 for phytochemistry, formulations and clinical trials. Manufacturing: five GMP dosage forms (powder, aerosol, plaster, capsule, toothpaste) with validated tech-transfer and CI cycles. Quality \u0026amp; safety: NMPA\/WHO GMP alignment, centralized pharmacovigilance and GS1 lot traceability. Commercial: omni-channel supply supporting China pharma market \u0026gt;RMB 1.2 trillion (2024).\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eR\u0026amp;D spend\u003c\/td\u003e\n\u003ctd\u003eRMB 1.02B (2023)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDosage forms\u003c\/td\u003e\n\u003ctd\u003e5 GMP forms\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eChina pharma market\u003c\/td\u003e\n\u003ctd\u003e\u0026gt;RMB 1.2T (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003eWhat You See Is What You Get\u003c\/span\u003e\u003cbr\u003e Business Model Canvas\u003c\/h2\u003e\n\u003cp\u003eThe Yunnan Baiyao Group Business Model Canvas you see here is the actual deliverable, not a mockup; it’s a live preview of the same document you’ll receive after purchase. Once you buy, you’ll instantly download this exact file—complete, editable, and formatted for Word and Excel—ready to present or adapt.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eR\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eesources\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Resources-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eFlagship brand and protected formulations\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eYunnan Baiyao’s century-old brand (founded 1902) and listing on Shenzhen (stock code 000538.SZ) underpin premium positioning and consumer trust. The secret core formula and proprietary manufacturing processes create strong product defensibility. Registered trademarks and patent filings protect format and extension play. Deep brand heritage lowers customer acquisition friction and supports higher margin channels.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Resources-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGMP production facilities and equipment\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eMulti-line plants enable diversified product forms and flexible output across oral, topical and injectable lines; Yunnan Baiyao Group (Shenzhen 000538.SZ) operates GMP-certified sites.\u003c\/p\u003e\n\u003cp\u003eValidated equipment and qualification protocols ensure consistent quality and regulatory compliance for domestic and export markets.\u003c\/p\u003e\n\u003cp\u003eHigh installed capacity and improved OEE underpin cost competitiveness, while a nationwide geographic footprint shortens lead times and reduces logistics risk.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Resources-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Resources-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSupply network and traceability systems\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eQualified herb suppliers and intermediates provide steady inputs to Yunnan Baiyao, supported by long-term contracts and regional cultivation partnerships. Digital traceability captures batch-level provenance from field to pack, enabling recalls and QC. Inventory management and cold-chain logistics protect temperature-sensitive formulations across distribution. The combined supplier network and systems are asset-heavy, hard to replicate and primed for scale-up.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Resources-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eScientific talent and regulatory know-how\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eTCM experts, pharmacists and formulation scientists (R\u0026amp;D headcount ~2,300 in 2024) drive Yunnan Baiyao Group innovation across herbal and biopharma pipelines. Medical affairs and regulatory teams secured multiple CFDA\/NMPA submissions in 2024, shortening approval cycles. Cross-functional expertise cut time-to-market, while knowledge capital compounds via ongoing clinical trials and real-world data.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eR\u0026amp;D headcount: ~2,300 (2024)\u003c\/li\u003e\n\u003cli\u003eMultiple NMPA submissions (2024)\u003c\/li\u003e\n\u003cli\u003eFaster approvals \u0026amp; shorter time-to-market\u003c\/li\u003e\n\u003cli\u003eData from trials builds reusable knowledge capital\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Resources-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eOmnichannel access and data assets\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eOmnichannel access—hospitals, pharmacies, and major e-commerce platforms—expands Yunnan Baiyao Group’s reach across clinical and consumer markets, while first-party sales and partner syndication data reveal demand patterns and customer cohorts. These insights guide product development and targeted marketing, and strengthen pricing and inventory decisions through cohort-level performance tracking.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eOmnichannel coverage\u003c\/li\u003e\n\u003cli\u003eFirst-party + partner data\u003c\/li\u003e\n\u003cli\u003eProduct \u0026amp; marketing insights\u003c\/li\u003e\n\u003cli\u003ePricing \u0026amp; inventory optimization\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Resources-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCentury-old TCM leader uses proprietary formula, GMP sites, \u003cstrong\u003e2,300\u003c\/strong\u003e R\u0026amp;D\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eYunnan Baiyao (founded 1902; 000538.SZ) leverages century-old brand equity, secret core formula and GMP plants to sustain premium margins. R\u0026amp;D headcount ~2,300 (2024) and multiple NMPA submissions accelerate pipelines. Nationwide supply chain, validated equipment and omnichannel sales cut lead times and lower customer acquisition costs.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue (2024)\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eFounding year\u003c\/td\u003e\n\u003ctd\u003e1902\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eStock code\u003c\/td\u003e\n\u003ctd\u003e000538.SZ\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eR\u0026amp;D headcount\u003c\/td\u003e\n\u003ctd\u003e~2,300\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGMP sites\u003c\/td\u003e\n\u003ctd\u003eMultiple\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eV\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003ealue Propositions\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Value-Propositions-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eClinically trusted hemostasis and pain relief\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eProven efficacy in controlling bleeding and reducing pain underpins clinical use, supported by extensive clinical and post-market surveillance; multiple formulations (powders, sprays, dressings) allow rapid, situation-appropriate application, while consistent performance across settings builds professional and consumer confidence and a strong safety profile documented in real-world evidence.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Value-Propositions-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eTCM heritage fused with modern science\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eTCM heritage fused with modern science: Yunnan Baiyao balances century-old formulations with GMP-level testing and ISO-aligned quality control, supporting a 2024 revenue of RMB 37.8 billion and driving credibility across channels. The portfolio delivers natural-ingredient solutions with consistent clinical validation, appealing to both conventional prescribers and wellness consumers amid a 2024 Chinese TCM market ~RMB 370 billion. This hybrid stance differentiates Yunnan Baiyao from purely synthetic pharma and artisan traditional peers by offering scale, regulatory compliance, and measurable efficacy.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Value-Propositions-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Value-Propositions-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eWide format portfolio for diverse needs\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eFrom powders and aerosols to plasters, capsules and toothpaste, Yunnan Baiyao’s wide-format portfolio fits varied use contexts and boosts portability for first-aid and on-the-go needs. Topical and systemic options broaden indications, supporting wound care and internal hemostasis; in 2024 the brand held about 30% share of China’s hemostatic plaster segment, aiding cross-selling through line extensions and bundled promotions.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Value-Propositions-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eReliable quality and nationwide availability\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eGMP production and strict QA deliver batch-to-batch consistency, underpinning Yunnan Baiyao Group’s reliable product quality; strong distribution networks ensure availability across urban and rural China, while e-commerce channels enable fast delivery and automatic replenishment so consumers find products where and when they need them.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eGMP-certified manufacturing\u003c\/li\u003e\n\u003cli\u003eNationwide distributor reach\u003c\/li\u003e\n\u003cli\u003eE-commerce fast replenishment\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Value-Propositions-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eEveryday wellness and personal care options\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eEveryday wellness and personal care leverage Yunnan Baiyao’s herbal credibility to position oral care and health-food SKUs as preventive complements to its therapeutic portfolio, driving routine use; in 2024 the group emphasized consumer healthcare to broaden mass-market reach. Bundled routines and affordable SKUs increase stickiness and lifetime value, supporting volume growth and channel penetration.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e000538.SZ brand heritage\u003c\/li\u003e\n\u003cli\u003ePreventive care complements Rx lines\u003c\/li\u003e\n\u003cli\u003eBundles raise retention\/LTV\u003c\/li\u003e\n\u003cli\u003eAffordable SKUs expand mass reach\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Value-Propositions-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eTCM hemostatic leader: \u003cstrong\u003eRMB 37.8bn\u003c\/strong\u003e, \u003cstrong\u003e~30%\u003c\/strong\u003e plaster share\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eProven hemostatic efficacy with multiple formulations, strong safety profile and real-world evidence supporting clinical and consumer trust.\u003c\/p\u003e\n\u003cp\u003eTCM heritage fused with GMP-quality science; Group revenue RMB 37.8 billion in 2024, positioning it uniquely vs traditional and synthetic peers.\u003c\/p\u003e\n\u003cp\u003eWide-format portfolio (powders, sprays, plasters, oral SKUs) and ~30% share of China hemostatic plaster segment in 2024 enable cross-sell and convenience.\u003c\/p\u003e\n\u003cp\u003eNationwide distributor reach plus e-commerce fast replenishment ensure availability across urban and rural markets.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003e2024\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eGroup revenue\u003c\/td\u003e\n\u003ctd\u003eRMB 37.8 billion\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eChina TCM market\u003c\/td\u003e\n\u003ctd\u003e~RMB 370 billion\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eHemostatic plaster share\u003c\/td\u003e\n\u003ctd\u003e~30%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eQuality \u0026amp; distribution\u003c\/td\u003e\n\u003ctd\u003eGMP-certified manufacturing; nationwide + e-commerce\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eC\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eustomer Relationships\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Relationships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eMedical engagement and support\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eMedical engagement combines detailing, CME, and clinical materials to support HCP decision-making, with Yunnan Baiyao Group (SZ:000538) leveraging field teams to respond to queries and collect case insights. Dedicated hospital liaisons build formulary access and ensure compliance across tertiary and provincial hospitals. Ongoing education programs sustain product usage and trust, aligned with the company’s 2024 commercial strategy.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Relationships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eConsumer education and community\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eContent on usage, safety, and wellness drives informed choices and reduces misuse, supported by consumer education programs that reference clinical guidelines and product labels. Social media, live streams, and forums leverage China’s 1.05 billion internet users (CNNIC, June 2024) to build active brand communities and scale outreach. First-aid tips and demonstrations improve outcomes and satisfaction, lowering care escalation and return rates. Two-way dialogue through comments and livestream Q\u0026amp;A fosters loyalty and converts users into advocates.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Relationships-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Relationships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLoyalty programs and subscriptions\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eLoyalty programs reward repeat purchases across Yunnan Baiyao’s oral care and wellness lines, driving cross-category spend and higher lifetime value. Subscriptions for toothpaste, plasters and supplements ensure continuity for frequently used items and reduce churn. Personalized offers based on member behavior increase retention and average basket size. Program data feeds product development and dynamic pricing strategies.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Relationships-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eOmnichannel customer service\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eOmnichannel customer service—hotlines, chat, and in-app support—resolves issues quickly and routes adverse-event reports to clinical teams. Clear, standardized guidance on indications, interactions, and proper usage reduces patient risk. Automated post-purchase follow-ups improve adherence and customer experience. Service SLAs are tailored by channel to meet response expectations.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eHotlines, chat, in-app triage\u003c\/li\u003e\n\u003cli\u003eIndications\/interactions guidance\u003c\/li\u003e\n\u003cli\u003eAutomated post-purchase follow-ups\u003c\/li\u003e\n\u003cli\u003eChannel-aligned SLAs\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Relationships-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eFeedback and safety monitoring\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eYunnan Baiyao structures collection of product reviews and adverse event reports through centralized digital channels and a pharmacovigilance unit, enabling rapid signal detection that triggers QA investigations and customer communications within agreed timelines. Co-creation initiatives engage users and practitioners in iterative product improvement, while transparent, documented responses and public safety summaries enhance brand credibility and regulatory trust.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eCentralized reporting portal\u003c\/li\u003e\n\u003cli\u003eRapid signal-to-QA workflow\u003c\/li\u003e\n\u003cli\u003eUser co-creation panels\u003c\/li\u003e\n\u003cli\u003ePublic safety summaries\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Relationships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHCP, hospital and consumer digital engagement tap China's \u003cstrong\u003e1.05 billion\u003c\/strong\u003e users for formulary access\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eCustomer relationships blend HCP-facing medical engagement, hospital liaisons and CME to secure formulary access and guideline-aligned usage support under Yunnan Baiyao Group (SZ:000538) 2024 commercial strategy. Consumer education, livestreams and community management leverage China’s 1.05 billion internet users (CNNIC, June 2024) to drive loyalty and reduce misuse. Centralized PV and digital service channels enable rapid signal detection, automated follow-ups and SLA-driven case handling.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eDigital reach\u003c\/td\u003e\n\u003ctd\u003e1.05 billion (CNNIC, Jun 2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTicker\u003c\/td\u003e\n\u003ctd\u003eSZ:000538\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eStrategy focus\u003c\/td\u003e\n\u003ctd\u003e2024 commercial \u0026amp; HCP engagement\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eC\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003ehannels\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Channels-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHospitals and clinical procurement\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eInstitutional sales to hospitals secure high-credibility usage and steady volume, with Yunnan Baiyao leveraged in over 36,000 Chinese hospitals by 2024 to drive clinical legitimacy. Inclusion in ER and surgical kits broadens exposure across acute care pathways, increasing product touchpoints during high-impact procedures. Medical reps provide on-site training and compliance support, while procurement cycles are managed through clinical evidence and service-level agreements to maintain formulary placement.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Channels-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRetail pharmacies and drugstores\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eRetail pharmacies and drugstores drive OTC visibility at the counter, fueling both impulse and planned purchases; in 2024 about 75% of China’s OTC market is routed through pharmacy channels, amplifying shelf-level exposure. Pharmacist recommendations remain a key conversion lever, with frontline advice shown to materially shift brand choice. In-store promotions and optimized planograms increase add-on conversion, while nationwide chains enable consistent execution and scale for Yunnan Baiyao’s portfolio.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Channels-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Channels-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eE-commerce marketplaces and DTC\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eFlagship stores on major platforms (Taobao\/Tmall reach ~1 billion users in 2023) provide reach and trust for Yunnan Baiyao, anchoring discovery and channel revenue. The DTC site enables richer product education and first-party data capture, boosting retention and personalized marketing. Subscriptions and curated bundles can raise purchase frequency and ARPU by ~20–30%. Fast delivery and visible reviews improve conversion rates by ~10–30%.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Channels-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDistributors and wholesalers\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eRegional distributors and wholesalers extend Yunnan Baiyao Group coverage into lower-tier cities and rural markets, managing inventory, credit and last-mile complexities; in 2024 their network helped sustain nationwide reach after the group reported ~RMB 23.8 billion revenue in 2023. Performance-based agreements with partners tie commissions to service KPIs, while aggregated logistics lower per-unit distribution costs and reduce stockouts.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eRegional reach: lower-tier \u0026amp; rural penetration\u003c\/li\u003e\n\u003cli\u003eOperations: inventory, credit, last-mile\u003c\/li\u003e\n\u003cli\u003eIncentives: performance-based contracts\u003c\/li\u003e\n\u003cli\u003eEfficiency: aggregated logistics cut costs, reduce stockouts\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Channels-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSocial commerce and live-streaming\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eKOL-led live demos educate consumers and create urgency, converting interest into purchases; China live-streaming e-commerce reached about RMB 1.2 trillion GMV in 2023, underscoring scale. Interactive sessions resolve concerns in real time, raising conversion and average order value. Limited-time offers accelerate sell-through while social proof from viewers and reviews amplifies brand credibility for Yunnan Baiyao.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003ekols\u003c\/li\u003e\n\u003cli\u003elive-demos\u003c\/li\u003e\n\u003cli\u003ereal-time-q\u0026amp;a\u003c\/li\u003e\n\u003cli\u003elimited-offers\u003c\/li\u003e\n\u003cli\u003esocial-proof\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Channels-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHospitals, pharmacies and mass e-commerce fuel \u003cstrong\u003eRMB 23.8bn\u003c\/strong\u003e revenue and \u003cstrong\u003eRMB 1.2tn\u003c\/strong\u003e live GMV\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eInstitutional sales: 36,000+ hospitals by 2024 ensure clinical reach and steady volumes. Pharmacy retail: ~75% of OTC flows through pharmacies in 2024, driving counter sales and pharmacist influence. E‑commerce\/DTC: Taobao\/Tmall ~1 billion users (2023) and DTC capture data for retention. Live commerce: China live-stream GMV ~RMB 1.2 trillion (2023), boosting conversion and AOV.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003cth\u003eYear\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eHospitals covered\u003c\/td\u003e\n\u003ctd\u003e36,000+\u003c\/td\u003e\n\u003ctd\u003e2024\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOTC via pharmacies\u003c\/td\u003e\n\u003ctd\u003e~75%\u003c\/td\u003e\n\u003ctd\u003e2024\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTaobao\/Tmall reach\u003c\/td\u003e\n\u003ctd\u003e~1 billion users\u003c\/td\u003e\n\u003ctd\u003e2023\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGroup revenue\u003c\/td\u003e\n\u003ctd\u003eRMB 23.8 bn\u003c\/td\u003e\n\u003ctd\u003e2023\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eLive-stream GMV\u003c\/td\u003e\n\u003ctd\u003eRMB 1.2 tn\u003c\/td\u003e\n\u003ctd\u003e2023\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eC\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eustomer Segments\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Segments-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHospitals, clinics, and emergency services\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eUsers include surgeons, ER staff and TCM departments relying on Yunnan Baiyao for rapid, reliable hemostasis. Institutional buyers in China’s ~36,000 hospitals (NHC 2023) prioritize demonstrated efficacy, safety and cost-effectiveness in procurement. Protocol-driven environments demand product consistency, clear training and integration into clinical pathways. Volume is steady, specification-based and tied to surgical caseloads measured in tens of millions annually.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Segments-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRetail pharmacies and pharmacists\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eRetail pharmacies and pharmacists prioritize fast-moving, trusted OTC SKUs with healthy gross margins and quick turnover; China had about 500,000 retail pharmacies in 2024, driving intense SKU competition. Pharmacists actively counsel customers and can sway purchase decisions, so relationship and training programs materially affect sell-through. Store networks require reliable supply and promotional support to secure shelf space, where category performance determines allocation and facings.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Segments-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Segments-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eConsumers seeking first-aid and pain relief\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eHouseholds seek accessible, effective first-aid and pain-relief products for minor injuries, favoring portable, easy-to-use formats that support on-the-spot care. Brand trust in Yunnan Baiyao reduces perceived risk and drives adoption, with repeat purchases following positive outcomes. With China population ~1.426 billion in 2024, household reach and frequency underpin stable OTC demand.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Segments-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eOral care and wellness shoppers\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eOral care and wellness shoppers buy Yunnan Baiyao toothpaste and health foods for daily routines and prevention; products emphasize breath care, gum protection, and adjunctive wellness positioning. Price tiers span value to premium SKUs to capture both mass and affluent segments. Consumers are sensitive to natural ingredients, taste and texture, and subscriptions suit habitual replenishment.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eDaily prevention focus\u003c\/li\u003e\n\u003cli\u003eTiered pricing: value to premium\u003c\/li\u003e\n\u003cli\u003eNatural-ingredient sensitivity\u003c\/li\u003e\n\u003cli\u003eSubscriptions for habit-based repurchase\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Segments-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSports, outdoor, and physically active users\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eAthletes and physically active workers demand fast-acting, portable haemostatic and analgesic solutions; product durability and plaster adhesion are critical for performance contexts. Strategic partnerships with sports clubs and event organizers in 2024 expanded on-the-ground reach, while community word-of-mouth across fitness groups increased trial and repeat purchase. Durable, sweat-resistant plasters drive higher conversion in field trials and retail channels.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eTarget: athletes, outdoor workers, fitness communities\u003c\/li\u003e\n\u003cli\u003eNeed: fast-acting, portable, high-adhesion plasters\u003c\/li\u003e\n\u003cli\u003eChannel: club\/event partnerships (2024 expansion)\u003c\/li\u003e\n\u003cli\u003eGrowth driver: community word-of-mouth\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Segments-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eIntegrated hemostasis \u0026amp; OTC oral care for hospitals, pharmacies, households and athletes\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eCore segments: hospital clinicians (36,000 hospitals, NHC 2023) needing proven hemostasis and protocol fit; retail pharmacies (≈500,000 stores in 2024) demanding fast-turn SKUs and trade support; households (China pop 1.426 billion in 2024) driving stable OTC repeat purchases; oral care\/wellness and athletes supply niche daily-prevention and performance needs.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eSegment\u003c\/th\u003e\n\u003cth\u003eReach\/size\u003c\/th\u003e\n\u003cth\u003eKey need\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eHospitals\u003c\/td\u003e\n\u003ctd\u003e36,000 (NHC 2023)\u003c\/td\u003e\n\u003ctd\u003eEfficacy, consistency\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRetail pharmacies\u003c\/td\u003e\n\u003ctd\u003e≈500,000 (2024)\u003c\/td\u003e\n\u003ctd\u003eFast turnover, promos\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eHouseholds\u003c\/td\u003e\n\u003ctd\u003ePopulation 1.426B (2024)\u003c\/td\u003e\n\u003ctd\u003eAccessible OTC\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eC\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eost Structure\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Cost-Structure-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eR\u0026amp;D and clinical validation\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eSpending on labs, clinical trials and external studies underpins product differentiation and drove Yunnan Baiyao Group to report about RMB 1.05 billion in R\u0026amp;D investment in 2024, financing CRO costs and in‑house validation. Regulatory submissions and comprehensive data packages add tens of millions RMB per NDA, raising fixed costs. Ongoing talent, IP protection and manufacturing transfer require continuous outlays, while portfolio management balances high trial risk against expected returns.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Cost-Structure-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRaw materials and sourcing\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eMedicinal herbs and actives show marked price and yield volatility—industry reports in 2024 cited swings up to 25% year‑on‑year—driving quality premiums and expanded laboratory testing that raise input costs by double‑digit percentages for leading TCM producers. Supplier development, traceability platforms and compliance add recurring overhead; maintaining buffer stocks (typically 2–6 months of cover) mitigates supply shocks.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Cost-Structure-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Cost-Structure-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eManufacturing and quality compliance\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eGMP-compliant production at Yunnan Baiyao Group (000538.SZ) drives high fixed costs from utilities and facility maintenance while variable costs rise with batch throughput. Validation, third-party audits and certifications are continuous requirements tied to regulatory inspections. Targeted automation investments aim to lower unit costs and improve yields. Scrap and yield losses are monitored closely through SPC and lean programs to protect margins.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Cost-Structure-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSales, marketing, and channel incentives\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eSales, marketing and channel incentives for Yunnan Baiyao hinge on medical reps, promotions and a co-op marketing fund driving demand; Chinese CPG firms commonly allocate 8–12% of revenue to marketing in 2024. E-commerce platform fees and commissions (typical range 5–20%) compress online margins, while trade discounts and rebates (often 10–20%) align distributor behavior. Sustained brand-building spend is required to maintain pricing power and channel preference.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eMedical reps, promotions, co-op fund\u003c\/li\u003e\n\u003cli\u003ePlatform fees\/commissions 5–20%\u003c\/li\u003e\n\u003cli\u003eTrade discounts\/rebates 10–20%\u003c\/li\u003e\n\u003cli\u003eBrand spend 8–12% of revenue (2024)\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Cost-Structure-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLogistics and distribution\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eFor Yunnan Baiyao (000538.SZ) logistics and distribution costs scale with warehousing, transportation and last-mile delivery volume; cold-chain or special handling for pharmaceuticals adds handling premiums and regulatory checks. Inventory holding and returns management tie up working capital, while route optimization and 3PL partnerships compress per-unit costs against rising parcel volumes — China handled ~113.7 billion express parcels in 2023.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eWarehousing: space + handling\u003c\/li\u003e\n\u003cli\u003eCold-chain: higher unit cost\u003c\/li\u003e\n\u003cli\u003eWorking capital: inventory \u0026amp; returns\u003c\/li\u003e\n\u003cli\u003eCost control: route optimization, 3PLs\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Cost-Structure-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003e\n\u003cstrong\u003eRMB 1.05bn\u003c\/strong\u003e R\u0026amp;D, \u003cstrong\u003e≈25%\u003c\/strong\u003e herb swings and 8–20% GTM hit margins\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eR\u0026amp;D 2024 at RMB 1.05bn drives fixed CRO and regulatory costs; ongoing IP, validation and trials raise overheads. Raw herb price swings (up to 25% YoY) and 2–6 months buffer stocks increase input and holding costs. Marketing\/GTN: brand spend 8–12% revenue, e‑commerce fees 5–20%, trade rebates 10–20% compress margins.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eCost item\u003c\/th\u003e\n\u003cth\u003e2024 metric\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eR\u0026amp;D\u003c\/td\u003e\n\u003ctd\u003eRMB 1.05bn\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eBrand spend\u003c\/td\u003e\n\u003ctd\u003e8–12% rev\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eE‑comm fees\u003c\/td\u003e\n\u003ctd\u003e5–20%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eHerb price volatility\u003c\/td\u003e\n\u003ctd\u003e≈25% YoY\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eR\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eevenue Streams\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Revenue-Streams-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCore hemostatic products\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eSales of powders, aerosols and plasters generate core hemostatic revenue for Yunnan Baiyao Group across clinical and consumer channels, with strong 2024 brand recognition supporting above-market pricing power.\u003c\/p\u003e\n\u003cp\u003eHigh repeat purchase rates stem from first-aid and routine medical use, while seasonal and event-driven spikes (sports, holidays, travel seasons) create predictable volume surges.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Revenue-Streams-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePrescription and OTC pharmaceuticals\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eYunnan Baiyao combines TCM and modern formulations targeting pain, inflammation and related indications, leveraging its SZSE:000538 brand heritage and R\u0026amp;D pipeline. Sales across hospital and retail channels diversify commercial risk and supported group revenue of about RMB 23.1 billion in 2023. New indications and formulations expand the TAM amid a China analgesics\/OTC pain market near RMB 120 billion in 2024. Regulatory compliance and chronic-use patterns underpin steady, recurring demand.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Revenue-Streams-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Revenue-Streams-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eOral care and personal care\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eToothpaste and related SKUs capture high-frequency daily-use occasions, with the global oral care market valued at about USD 40.6 billion in 2023 and China representing roughly a quarter of that market by 2024. Cross-selling leverages the Yunnan Baiyao flagship brand halo to lift penetration across channels, boosting basket size; branded oral-care contributes materially to group consumer revenue. Premium functional variants (sensitivity, whitening, herbal) increase ASPs by double-digit premiums, while subscription offerings—growing industry-wide by ~20% year-over-year—stabilize recurring cash flow.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Revenue-Streams-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHealth foods and supplements\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eHealth foods and supplements tap rising preventive-health spend in China, with the dietary-supplement market exceeding RMB 300 billion in 2024 and e-commerce accounting for roughly 40–50% of sales; natural-ingredient SKUs command premium pricing and higher margins. Bundles and seasonal packs increase basket size and AOV, while regulatory-approved claims and TCM heritage bolster credibility and repeat purchases.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eMarket size: \u0026gt;RMB 300bn (2024)\u003c\/li\u003e\n\u003cli\u003eE-commerce share: ~40–50%\u003c\/li\u003e\n\u003cli\u003eRevenue drivers: bundles, seasonals, repeat-buy programs\u003c\/li\u003e\n\u003cli\u003eTrust levers: regulatory claims, TCM brand equity\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Revenue-Streams-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eInternational and cross-border sales\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eInternational and cross-border sales leverage exports and cross-border e-commerce to reach overseas TCM users, with select regulatory registrations enabling entry into targeted markets. Initial traction is driven by Chinese diaspora channels and the global wellness segment, while strategic partnerships lower localization and compliance costs. This model prioritizes focused market entry and cost-efficient scaling.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eExports via cross-border e-commerce\u003c\/li\u003e\n\u003cli\u003eTargeted registrations for market access\u003c\/li\u003e\n\u003cli\u003eDiaspora and wellness-led demand\u003c\/li\u003e\n\u003cli\u003ePartnerships to cut localization\/compliance costs\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Revenue-Streams-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHemostatics \u0026amp; OTC: group RMB \u003cstrong\u003e23.1bn\u003c\/strong\u003e, analgesics RMB \u003cstrong\u003e120bn\u003c\/strong\u003e\n\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eCore hemostatic products drive recurring clinical and retail sales; group revenue was ~RMB 23.1bn in 2023, with analgesics\/OTC pain market ~RMB 120bn in China (2024). Oral-care SKUs tap daily-use demand (global market USD 40.6bn in 2023; China ~25% by 2024). Supplements exploit a \u0026gt;RMB 300bn market (2024) with e-commerce 40–50% share and subscription growth ~20% YoY.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eGroup revenue (2023)\u003c\/td\u003e\n\u003ctd\u003eRMB 23.1bn\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eChina analgesics\/OTC (2024)\u003c\/td\u003e\n\u003ctd\u003eRMB 120bn\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSupplements market (2024)\u003c\/td\u003e\n\u003ctd\u003e\u0026gt;RMB 300bn\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOral care (global 2023)\u003c\/td\u003e\n\u003ctd\u003eUSD 40.6bn\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e","brand":"PESTEL Analysis","offers":[{"title":"Default Title","offer_id":58098540249436,"sku":"ynbaiyao-business-model-canvas","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0938\/8127\/0620\/files\/ynbaiyao-business-model-canvas.png?v=1781810295","url":"https:\/\/pestel-analysis.com\/products\/ynbaiyao-business-model-canvas","provider":"PESTEL ANALYSIS","version":"1.0","type":"link"}